# Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose

> **NCT00891813** · PHASE4 · COMPLETED · sponsor: **Abbott** · enrollment: 100 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Renal Insufficiency, Chronic
- Parathyroid Hormone
- Hemodialysis
- Hypercalcemia

## Interventions

- **DRUG:** Zemplar (paricalcitol)

## Key facts

- **NCT ID:** NCT00891813
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2011-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00891813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00891813, "Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00891813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*